ClinicalTrials.gg
RecruitingNCT04289467Updated Apr 15, 2026

Treatment of Refractory Infantile Spasms With Fenfluramine

A Phase 2 interventional study of Fenfluramine in Infantile Spasm, sponsored by Children's Hospital of Orange County. Recruiting at 2 sites in United States. Open to participants aged 12 Months to 36 Months. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Children's Hospital of Orange County · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
12 Months to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Spasms, Infantile with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Spasms, Infantile · United States.

Planned enrollment
9th of 18
10 · median 10
Started
2023
with 1 other
Phase 2
7 of 22
2 open now
Registered
16th of 22
by date
Lead sponsor
1 of 22
Children's Hospital of Orange County

Among the 22 studies in Spasms, Infantile with a site in United States, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 2, and was the 16th registered.

Spasms, Infantile

47 studies on the registry are indexed under Spasms, Infantile; 8 are open to participants now.

Browse Spasms, Infantile studies →

Open to participants now

2 of the 22 studies in Spasms, Infantile with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Spasms, Infantile studies recruiting now, none set no upper age limit and 8 stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 12 Months to 36 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Spasms, Infantile with a site in United States, or all of them as a file.
02

Study summary

This is a phase II clinical trial in which children with refractory infantile spasms (also called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to treatment with vigabatrin and ACTH we will be invited to participate. Study participants will undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo repeat video-EEG to determine effectiveness. Patients with favorable response will have the opportunity to continue treatment for up to 6 months.

03

Conditions studied

  • Infantile Spasm

Browse trials for

04

Who can participate

Ages eligible
12 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children ages 12 to 36 months, inclusive
  • Clinical diagnosis of infantile spasms
  • Continued epileptic spasms despite adequate treatment with ACTH and vigabatrin.

Exclusion criteria

Exclusion Criteria:

  • Significant preexisting cardiovascular disease
  • Exposure to any cannabinoid product within 14 days of screening
  • Initiation or dose-titration of any treatment for infantile spasms in the 14 days prior to screening.
  • Implantation of a vagal nerve simulator within 14 days of screening
  • Initiation and maintenance of the ketogenic diet within 3 months of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Fenfluramine treatment

    Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.

    Drug: Fenfluramine

Interventions

  • Open-label

    Also known as: Fenfluramine Hydrochloride

06

What researchers measure

Primary outcomes

  1. Electroclinical response (Efficacy)

    Number of participants with resolution of epileptic spasms and hypsarrhythmia (if present at baseline) after 21 days of treatment, as determined by overnight video-electroencephalography (EEG) evaluation and caregiver seizure diary.

    Time frame: 12 months

Secondary outcomes

  1. Computational electroencephalography response (Efficacy)

    Median and range of response quantified using the probability-weighted response index (PWRI), a novel computational electroencephalography measure of hypsarrhythmia burden.

    Time frame: 12 months

  2. Incidence of treatment emergent adverse events (Safety and tolerability)

    Detailed accounting of all treatment-emergent adverse events, including number of participants with clinically-significant valvulopathy and/or pulmonary hypertension, as determined by echocardiography.

    Time frame: 12 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2020
First posted
Feb 28, 2020
StartActual
Jun 16, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04289467
Lead sponsor
Children's Hospital of Orange County
Responsible party
Daniel Shrey (Associate Professor, Children's Hospital of Orange County) — Principal investigator
First posted
Feb 28, 2020
Start date
Jun 16, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 15, 2026

Study contacts

Kellie Bacon, MPH
Contact
kellie.bacon@choc.org
714-509-8972
Virginia Allhusen, PhD
Contact
vallhusen@choc.org
Daniel Shrey, MD
principal investigator · Children's Hospital of Orange County

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion